US EditionKailera Therapeutics' $625M IPO ranks among biggest ever - Boston ...
The biotech priced shares at the top of its range as investor demand pushed the deal above its $500 million target.
- On Friday, Waltham, Massachusetts-based Kailera Therapeutics began trading on the Nasdaq under ticker KLRA, raising $625 million in one of the sector's largest-ever initial public offerings.
- Founded in 2024, the biotech is led by former Cerevel Therapeutics CEO Ron Renaud and has secured backing from prominent investors including Bain Capital, Atlas Venture, and Arch Venture Partners.
- The company's lead program, ribupatide, is a dual GIP and GLP-1 agonist designed to have a "superior" clinical profile compared to Eli Lilly's Zepbound, per Kailera's filing.
- By advancing both injectable and oral treatments, Kailera aims to address a broader range of patient needs within an obesity market projected to reach $200 billion by 2030.
- The listing surpasses Sana Biotechnology's $588 million issuance in 2021, and Kailera plans to use proceeds to fund three ongoing Phase 3 trials of ribupatide.
12 Articles
12 Articles
From drought to demand: Biotech IPOs roar back with Kailera and Alamar
Yuling Luo rang the Nasdaq closing bell Friday having taken his first company public in a massively oversubscribed round. The Alamar Biosciences CEO’s IPO was one of two back-to-back blockbuster biotech offerings this week, a clear signal that investors are willing to open their wallets for life sciences companies again—under the right conditions. On Thursday, Kailera Therapeutics, an obesity drug developer, raised $625 million in what is believ…
Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs
Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
